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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S310Conclusion: In conclusion, although a similar rate of attrition
was seen in donors overall, the reasons were different from
our previous study. Two of the changes instituted are likely
to have contributed (lowering joining age and increasing
BMI). Further work must be done on understanding other
factors associated with attrition, and collaborating with
other international registries to permit access to donors who
have moved to other countries.448
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Disease relapse, graft vs host disease and infection remain
the major barriers to successful allogeneic stem cell trans-
plantation. We previously presented data on the use of
escalated AUC based dosing of a continuous infusion (CI) of
IV busulfan over four days (Walko, BBMT, S218, 2012). In that
report, we described use of a test dose and day 1 and 4 PK
values to determine the dose delivered, and identiﬁed dose
limiting toxicities as rash and mucositis at an AUC of
8300 um-min/day and identiﬁed an AUC MTD of approxi-
mately 6912 uM-min/day x 4 days; a 40% increase over a
standard AUC dose of 4800 uM-min/day. Here we report
additional analyses to identify patients (pts) likely to beneﬁt
from this higher dose of continuous infusion busulfan.
Methods: Patients with advanced hematologic malignancies
and adequate organ function who were appropriate for a
MUD or MRD allogeneic transplant were enrolled on an IRB
approved trial of a test dose of busulfan (.8 mg/kg x 1) fol-
lowed by escalated dose busulfan (4800-8300 uM-min/d)
given as a 90 hour continuous infusion along with ﬂudar-
abine at 30 mg/m2/d x 5. Pts received tacrolimus and either
alemtuzamab (30), ATG + MTX (19) or MTX alone (6) as GVH
prophylaxis with standard anti-infective and supportive
care.
Results: 55 pts (median age 41, range 20-55) with myeloid
(38), lymphoid (8), or biphenotypic (1) leukemias, MDS or
MF (1) or lymphomas (7) were enrolled. All 55 subjects
were analyzed according to their being in the AUC low
(group 1, 19 pts), middle (group 2, 19 pts), or high dose
(group 3, 17 pts). 17 subjects had low, 20 had intermediate,
and 18 had high-risk disease by CIBMTR criteria. For the
entire group, univariate analysis identiﬁed age, recipient
CMV status, and disease risk as signiﬁcant factors for overall
(OS) and relapse free survival (RFS). Co-morbidity scores,
GVH occurrence or prophylaxis, donor/recipient sex and
donor type (MUD or MRD) were not signiﬁcant, nor was the
non-relapse mortality rate different between the three AUCgroups. Multivariable analysis identiﬁed CMV status as
borderline signiﬁcant (p¼.07), and high vs low AUC dose
(p¼.053) and disease risk (p¼.01) as signiﬁcant for both OS
and RFS. Outcomes were similar between AUC groups 2 and
3. Differences in OS and RFS were limited to the good and
intermediate risk patients as outcomes for high-risk pa-
tients were poor for all AUC groups (0/17 RFS and 1/17 OS).
When analyzing the 38 good and intermediate risk patients,
the OS and RFS were 66% and 62.5% for combined AUC
groups 2 and 3 compared to 31% (p¼.02) for both OS and
RFS in AUC group 1.
Conclusions: Targeted, PK based, CI busulfan that is
approximately 40% higher than standard doses can result in
apparent beneﬁt for patients with CIBMTR low or interme-
diate risk disease. These doses were unable to demonstrate
beneﬁt in high-risk patients for whom other approaches
such as immunotherapy, hypomethylating agents, or small
molecule inhibitors may be needed.449
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Several risk scores have been developed for the prediction
of transplant related mortality (TRM) following allogeneic
hematopoietic stem cell transplantation (HSCT). These have
been validated; however, predictive performance is sub-
optimal. In addition to inherent uncertainty in such a
complex medical procedure, methodological factors
impeding prediction might be attributed to the statistical
methodology, number and quality of features collected, or
simply the population size. Using an in-silico approach (i.e.
iterative computerized simulations), based on machine
learning (ML) algorithms, we set to explore the factors
limiting prediction.
ML is a subﬁeld of computer science and artiﬁcial intelli-
gence that deals with the construction and study of systems
that can learn from data, rather than follow explicitly pro-
grammed instructions. Commonly applied in complex data
scenarios, such as ﬁnancial and technological settings, it may
be suitable for outcome prediction of HSCT.
Study design involved two phases. The ﬁrst, focused on
development of several ML based prediction models of day
Figure 1. Predictive performance of TRM prediction models, adjusted for small size
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S311100 TRM. A cohort of 28,236 acute leukemia, adult allogeneic
HSCT recipients were analyzed. Twenty four variables were
included. In the second phase, by applying a repetitive
computerized simulation, factors necessary for optimal pre-
diction were explored: algorithm type, size of data set,
number of included variables, and performance in speciﬁc
subpopulations. Models were assessed and compared on the
basis of the area under the receiver operating characteristic
curve (AUC).
We developed 6 ML based prediction models for day 100
TRM. Optimal AUCs ranged from 0.65-0.68. Predictive per-
formance plateaued for a population size ranging from
n¼5647-8471, depending on the algorithm (Figure 1). A
feature selection algorithm ranked variables according to
importance. Provided with the ranked variable we data,
discovered that a range of 6-12 ranked variables
were necessary for optimal prediction, depending on the
algorithm. Predictive performance of models developed for
speciﬁc subpopulations ranged from an average of 0.59 to
0.67 for patient in second complete remission and patients
receiving reduced intensity conditioning respectively.
In summary, we present a novel computational approach
for predictionmodel development and analysis in the ﬁeld of
HSCT. Using data commonly collected on transplant patients,
our simulation elucidates outcome prediction limiting fac-
tors. Regardless of the methodology applied, predictive per-
formance converged when sampling more than 5000
patients. Few variables “carry the weight” with regard to
predictive inﬂuence. Overall, the presented ﬁndings reveal a
phenomenon of predictive saturation with data traditionally
collected. Improving predictive performance will likely
require additional types of input like genetic, biologic and
procedural factors.Table 1
Characteristics %
Low risk
(n¼18)
High risk
(n¼18)
Donor Related 17 28
Unrelated 83 72
AL Myeloid 78 67
Lymphoid 22 33
CR# 1st 67 61
2nd 33 39
Conditioning High-dose 50 39
Reduced-intensity 50 61450
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Michigan, Ann Arbor, MIThe HCT-comorbidity index (CI) was developed as a
measure of health-status that could stratify risks of
mortality after HCT. There is a great need for novel
biomarkers that could explain the biologic link but also
increase the objectivity of diagnosing pre-HCT comor-
bidities and increase the predictive power for post-HCT
mortality. MiRs are a class of small non-coding RNAs
(w22 nt) that negatively regulate gene expression.
Studies have uncovered the functional role of miRs in
diverse pathophysiological processes. Moreover, a single
miR could be implicated in different pathological pro-
cesses. To this end, we analyzed miRs as diagnostic for
comorbidities before and as prognostic for mortality
after HCT.
Peripheral blood mononuclear cell samples were pre-
viously collected from 36 pts within 30 days prior to
HCT as a part of research repository. All samples were
collected in EDTA tubes and processed and frozen at -80
Celsius degrees within 8 hours of draw. All pts were in
CR before HCT. Low risk was deﬁned as having HCTCI
score of 0 before and surviving after HCT (median
follow up 56 month, range 12.5-75.5), while high-risk
pts had scores of 4-9 before HCT and none of them
survived HCT (Table 1).
RNA was isolated from PBMC using previously
described methods (Xie LN et al, Clinical Transplant.
2014; 28:314). For discovery of relevant miRs, we used
NanoString nCounter miR assay as previously described
(Knouf EC et al, 2013. PLoS ONE 8: e69630) comprising
654 endogenous miRs. Analysis of miR raw data was
done using nSolverTM 2.0 Software (NanoString Tech-
nologies, Inc.) applying standard quality control tests. All
samples contributed to the discovery analysis. MiRs
